Page 4 - Ncertainties And Other Factors That May Cause Our Actual Results News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ncertainties and other factors that may cause our actual results. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ncertainties And Other Factors That May Cause Our Actual Results Today - Breaking & Trending Today

Telix Acquires Optimal Tracers

MELBOURNE, Australiaand INDIANAPOLIS, Ind., Nov. 14, 2022 /PRNewswire/ Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company)today announces that it has entered into an agreement with Sacramento-based Northern California PET Imaging Center (NCPIC) to acquire Optimal Tracers, a radiochemistry development business providing radiochemistry process development services and research tracers for use in clinical trials. The acquisition of Optimal Tracers will bolster Telix's in-house radiochemistry development capability, by adding a highly skilled team to Telix and establishing a U.S.-based laboratory and production footprint for clinical trial doses. The acquisition includes a facilitywith a radiation and pharmaceutical manufacturing licence sufficient to cover the Company's key diagnostic and therapeutic isotope requirements for pre-clinical and clinical research purposes. The acquisition of Optimal Tracers aligns with Telix's strategy to build a degree of vertical inte ....

United States , United Kingdom , Kyahn Williamson , Jonathan Barlow , Ruth Tesar , University Of California , Telix Pharmaceuticals , Drug Administration , Australian Securities Exchange , Prnewswire Telix Pharmaceuticals Limited , Australian Therapeutic Goods Administration , Imaging Center , Corporate Communications , Global Business Development Alliance Management , Health Canada , Pharmaceuticals Limited , Sacramento Based Northern California , Optimal Tracers , West Coast , Business Development , Alliance Management , Optimal Tracer , Northern California , Telix Pharmaceuticals Limited , Ustraliaand Indianapolis , Nov 14 ,

First Patient Dosed in Phase II 'IPAX-Linz' Study of TLX101 for Glioblastoma Therapy

MELBOURNE, Australia, Nov. 22, 2022 /PRNewswire/ Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company)today announces that a first patient has been dosed in a Phase II investigator-initiated study of TLX101 in combination with external beam radiation therapy (EBRT) in patients with recurrent high-grade gliomas (HGG), including glioblastoma multiforme (GBM). TLX101 (4-L-[131I] iodo-phenylalanine, or 131I-IPA) is one of Telix's lead therapeutic clinical programs and has been granted orphan drug designation in the U.S. and Europe. TLX101 targets L-type amino acid transporter 1 (LAT-1), typically over-expressed in many malignant tumours, including HGG/GBM. The IPAX-Linz study, which is being led by Professor Josef Pichlerat Kepler University Hospital in Linz, Austria, builds on data generated in the IPAX-1 study. The final results of the IPAX-1 study, reported in September 2022, demonstrated a favourable safety profile and encouraging preliminary therapeutic effect.[1] IPAX-Lin ....

United States , United Kingdom , Ordensklinikum Linz , Kyahn Williamson , Colin Hayward , Barmherzige Schwestern , Josef Pichler , Christian Behrenbruch , Telix Pharmaceuticals , Kepler University Hospital , Kepler University Hospital In Linz , Drug Administration , Australian Securities Exchange , Australian Therapeutic Goods Administration , Corporate Communications , Telix Pharmaceuticals Limited , Health Canada , Professor Josef Pichler , Principal Investigator , Chief Medical Officer , Managing Director , Group Chief Executive , Nov 22 , 022 Prnewswire Telix Pharmaceuticals Limited Asx Tlx , He Company Today Announces Thata First Patient Has Been Dosed Ina Phase Ii Investigator Initiated Study Of Tlx101 In Combination With External Beam Radiation Therapy Ebrt Patients Recurrent High Grade Gliomas Hgg , Ncluding Glioblastoma Multiforme Gbm Tlx101 4l 131i Iodo Phenylalanine ,

Chinese NMPA Approves Pivotal Phase III Study of TLX591-CDx for Prostate Cancer Imaging

MELBOURNE, Australia, Oct. 17, 2022 /PRNewswire/ Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company)today announces that the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has approved an investigational new drug (IND) application to commence a pivotal Phase III registration study of TLX591-CDx (Kit for the preparation of 68Ga-PSMA-11), for the imaging of prostate cancer using Positron Emission Tomography (PET) that will bridge to the marketing authorisation granted to Illuccix by the United States Food and Drug Administration (FDA). The IND application was submitted in partnership with Grand Pharmaceutical Group Limited (Grand Pharma), Telix's partner in the Greater China region. The bridging study is required to provide data obtained in a Chinese population to establish that the diagnostic efficacy of TLX591-CDx is equivalent in Chinese and Western populations. This study will enroll up to 110 patients with suspected recurrent ....

United States , United Kingdom , Cdx Illuccix , Kyahn Williamson , Davidn Cade , Telix Asia Pacific , Telix Pharmaceuticals , Drug Administration , Australian Securities Exchange , Prnewswire Telix Pharmaceuticals Limited , Australian Therapeutic Goods Administration , Group Limited Grand Pharma , Chinese National Medical Products Administration , Corporate Communications , Health Canada , Pharmaceuticals Limited , Drug Evaluation , Positron Emission Tomography , United States Food , Grand Pharmaceutical Group Limited , Grand Pharma , Greater China , Asia Pacific , Prostate Cancer , Telix Pharmaceuticals Limited , Oct 17 ,

Telix APAC Report: Regulatory Progress for Prostate and Kidney Cancer Imaging

MELBOURNE, Australia, Aug. 2, 2022 /PRNewswire/ Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today reports on regulatory progress for the Company's core prostate and kidney cancer imaging programs in the Asia Pacific (APAC) Operating Region, including progress in the major market of China with its strategic partner Grand Pharmaceutical Group Limited (Grand Pharma). TLX591-CDx (Illuccix) for prostate cancer imaging China: An Investigational New Drug (IND) application has been submitted by Telix's partner in Greater China, Grand Pharma, to the National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) - and accepted for review - for a pivotal Phase III registration study that will bridge to the United States Food and Drug Administration (FDA) approval of Illuccix. South Korea: As previously reported, an imported New Drug Application (NDA) has been submitted by Telix's partner in South Korea, DuChemBio Co, Ltd. (DuChemBio), to the Minist ....

United States , South Korea , Cdx Illuccix , Kyahn Williamson , Davidn Cade , Telix Asia Pacific , Asia Pacific , Christian Behrenbruch , Telix Pharmaceuticals , Drug Administration , Australian Securities Exchange , Prnewswire Telix Pharmaceuticals Limited , Australian Therapeutic Goods Administration , Group Limited Grand Pharma , Corporate Communications , Duchembio Co Ltd , National Medical Products Administration , Ministry Of Food , Pharmaceuticals Limited , Operating Region , Grand Pharmaceutical Group Limited , Grand Pharma , Greater China , Drug Evaluation , United States Food , New Drug Application ,